Abbott Laboratories has pled guilty to civil and criminal charges of illegally marketing Depakote for the control of agitation and aggression in elderly patients with dementia (referred to as “elder abuse” by one U.S. attorney), as well as for the treatment of schizophrenia. Abbott will undergo court-supervised probation and reporting obligations by Abbott’s CEO and board of directors.
Abbott Laboratories to Pay $1.5B for Off-Label Drug Marketing (Law.com)
Abbott Pleads Guilty To Misbranding; Will Pay $1.6 Billion (MediaPost)
Abbott Laboratories settles Depakote case for $1.6 billion (Chicago Tribune)
Abbott settles complaint over schizophrenia drug (Sacramento Bee)
Nebraska to get nearly $5M in Abbott settlements (CBS Money Watch)
Oregon to reap $6 million over alleged unlawful drug marketing with Portland link (Oregonlive.com)
Utah receiving $4 million in drug settlement (CBS Money Watch)
Idaho settles illegal marketing case for $1.2 M with maker of anti-psychotic drug Depakote (The Republic)
Mad in America hosts blogs by a diverse group of writers. These posts are designed to serve as a public forum for a discussion—broadly speaking—of psychiatry and its treatments. The opinions expressed are the writers’ own.
Mad in America has made some changes to the commenting process. You no longer need to login or create an account on our site to comment. The only information needed is your name, email and comment text. Comments made with an account prior to this change will remain visible on the site.